Bokhari says the Canadian company is 'hunkering down' on its cannabis grow facility and 'doubling down' on its biosciences effort, advancing its Phase 1 safety trials for its lead drug candidate PP 101 micro-PEA.
Full interview: FSD Pharma 'hunkering down' on grow facility and 'doubling down' on biosciences effort
Quick facts: FSD Pharma
Price: 2.63 CAD
Market Cap: $50.4 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE